Solutions
Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Inquiry

Alport Syndrome

Alport syndrome is a rare genetic disorder that manifests as a debilitating combination of kidney disease, hearing loss, and eye abnormalities. It is caused by mutations in genes encoding type IV collagen, a key component of the basement membrane in the kidneys, ears, and eyes. Our company stands at the forefront of advancements in the field of rare diseases, offering a comprehensive suite of services covering genetic analysis and disease modeling to therapeutic development.

Overview of Alport Syndrome

With a prevalence ranging from 1 in 5000 to 1 in 50,000 individuals, Alport syndrome affects both males and females, with an X-linked inheritance pattern being the most common. The syndrome can present in childhood or later in life, and its severity can vary widely among individuals. Common symptoms include blood in the urine (hematuria), proteinuria, progressive kidney dysfunction, high-frequency hearing loss, and ocular abnormalities such as lens dislocation and retinopathy.

Alport syndrome includes kidney, auditory, and ocular involvement.Fig.1 Symptoms and GBM features observed in Alport syndrome. (Gregorio, V., et al., 2023)

Pathogenesis of Alport Syndrome

Alport syndrome is primarily caused by mutations in genes encoding type IV collagen, namely COL4A3, COL4A4, and COL4A5. Type IV collagen is essential for maintaining the structural integrity of the basement membrane in the kidneys, ears, and eyes. Mutations in these genes disrupt the formation and function of type IV collagen, leading to basement membrane abnormalities, impaired filtration in the kidneys, and progressive renal damage.

Pathogenesis of Alport syndrome.Fig.2 Type IV collagen from gene to protein trimerization to disease. (Gregorio, V., et al., 2023)

Biomarkers Development of Alport Syndrome

Genetic testing by DNA sequencing technologies, such as next-generation sequencing plays a crucial role in confirming the diagnosis, identifying the specific genetic mutations, and determining the mode of inheritance. In addition, biomarkers can also provide information about the presence, severity, or progression of a disease, there are some potential biomarkers commonly associated with Alport syndrome.

  • Vascular endothelial growth factor A
  • High motility group box 1
  • Epidermal growth factor
  • Urinary monocyte chemoattractant protein-1
  • Transforming growth factor beta 1
  • Urinary podocin

Therapeutics Development of Alport Syndrome

Agents Types Mechanism Research Phase
Sparsentan Small molecule inhibitor Dual endothelin angiotensin receptor antagonist Phase II trials
Atrasentan Small molecule inhibitor Endothelin A receptor antagonist Phase II trials
ELX-02 Aminoglycoside analog Correct nonsense variants Phase II trials
R3R01 Lipid-modifying drug A novel lipid-modifying agent Phase II trials
Hydroxychloroquine sulfate (HCQ) Small molecule drug Suppressed the activation of toll-like receptors on the surface of endosomes Phase II trials
Bardoxolone Methyl Small molecule drug Activation of Nrf2 and inhibition of NF-κB Phase III trials
Exon skipping therapy Gene therapy Restore gene function Preclinical research

Our Services

With an unwavering commitment to the study and understanding of rare diseases, we possess animal models and therapeutic development platform that enables us to provide comprehensive services tailored to the unique needs of researchers in this field.

Therapy Development Platforms

Animal Models of Alport Syndrome

Animal models of Alport syndrome play a crucial role in advancing our understanding of the disease, elucidating its pathogenesis, and testing potential therapeutic interventions. Our company can provide a variety of animal models to help you develop targeted therapies and advance personalized drug for individuals affected by Alport syndrome.

Animal models of Alport syndrome.

Genetically Engineered Models

Genetic engineering techniques such as CRISPR/Cas9 are used to create animal models of Alport syndrome that closely mimic specific genetic mutations found in human individuals.

Optional Models: Col4a3tm1Jhm model; Col4a5em1Keha model; Col4a4bwk model, etc.

Optional Species: Mice, Rats, Zebrafish, Non-Human Primates, Others

Our multidisciplinary team of experts combines cutting-edge scientific knowledge with state-of-the-art technologies to deliver innovative solutions and insights. We provide comprehensive services including pharmacokinetic studies and drug safety evaluation, to promote the understanding, diagnosis, and therapy of rare diseases.

If you are interested in learning more about our services and how we can support your research endeavors, please do not hesitate to reach out to us for further information.

References

  • Gregorio, Vanessa De et al. "Alport Syndrome: Clinical Spectrum and Therapeutic Advances." Kidney medicine 5.5 (2023): 100631.
  • Gomes, Ana Marta et al. "Potential Renal Damage Biomarkers in Alport Syndrome-A Review of the Literature." International journal of molecular sciences 23.13 (2022): 7276.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Copyright © Protheragen. All rights reserves.